Effect of several compounds on biliary excretion of paclitaxel and its metabolites in guinea-pigs

Anti-Cancer Drugs

Volumn 16, Issue 6, 2005, Pages 675-682

  Bun, Sok Siya ^a   Giacometti, Sarah ^a   Fanciullino, Raphaëlle ^a   Ciccolini, Joseph ^a   Bun, Hot ^a   Aubert, Claude ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Biliary elimination; Drug drug interactions; Guinea pigs; Paclitaxel metabolism

Indexed keywords

3' HYDROXYPACLITAXEL; 6ALPHA HYDROXYPACLITAXEL; 6ALPHA,3' DIHYDROXYPACLITAXEL; COTRIMOXAZOLE; DEXAMETHASONE; DRUG METABOLITE; KETOCONAZOLE; PACLITAXEL; QUERCETIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE SECRETION; BILIARY EXCRETION; CONTROLLED STUDY; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSFORMATION; FEMALE; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SPECIES DIFFERENCE;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; BILE; BIOTRANSFORMATION; DEXAMETHASONE; DOGS; DRUG INTERACTIONS; GLUCOCORTICOIDS; GUINEA PIGS; HUMANS; KETOCONAZOLE; LIVER; MACACA FASCICULARIS; MALE; MICE; MICROSOMES, LIVER; MODELS, ANIMAL; PACLITAXEL; QUERCETIN; RABBITS; RATS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 20844435764     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200507000-00013     Document Type: Article

References (26)

1. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997; 48:353-374.
2. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994; 54:386-392.
3. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Guerritte F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 2002; 30:438-445.
4. Harris JW, Katki A, Anderson LW, Chmurny GN, Paukstelis JV, Collins JM. Isolation, structural determination, and biological activity of 6α-hydroxytaxol, the principal human metabolite of Taxol. J Med Chem 1994; 37:706-709.
5. Kumar G, Ray S, Walle T, Huang Y, Willingham M, Self S, et al. Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6α-hydroxytaxol. Cancer Chemother Pharmacol 1995; 36:129-135.
6. Jamis-Dow CA, Klecker RW, Katki AG, Collins JM. Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 1995; 36:107-114.
7. Vaclavikova R, Horsky S, Simek P, Gut I. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn Schmiedebergs Arch Pharmacol 2003; 368:200-209.
8. Monsarrat B, Mariel E, Cros S, Gares M, Guenard D, Gueritte-Voegelein F, et al. Taxol metabolism: isolation and identification of three major metabolites of taxol in rat bile. Drug Metab Dispos 1990; 18:895-901.
9. Monsarrat B, Alvinerie P, Wright M, Dubois J, Gueritte-Voegelein F, Guenard D, et al. Hepatic metabolism and biliary excretion of taxol in rats and humans. J Natl Cancer Inst Monogr 1993; 15:39-46.
10. 3H]taxol in the Sprague-Dawley rat. Drug Metab Dispos 1994; 22:254-258.
11. Van der Hoeven TA, Coon MJ. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 1974; 249:6302-6310.
12. Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J. Drug interactions of paclitaxel metabolism in human liver microsomes. J Chemother 2003; 15:266-274.
13. Huizing MT, Sparreboom A, Rosing H, Van Tellingen O, Pinedo HM, Beijnen JH. Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995; 674:261-268.
14. Sparreboom A, Van Tellingen O, Nooijen WJ, Beijnen JH. Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs 1996; 7:78-86.
15. Chaïb S, Charrueau C, Neveux N, Coudray-Lucas C, Cynober L, De Bandt JP. Isolated perfused liver model: the rat and guinea pig compared. Nutrition 2004; 20:458-464.
16. Kerdpin O, Elliot DJ, Boye SL, Birkett DJ, Yoovathaworm K, Miners JO. Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. Biochemistry 2004; 43:7834-7842.
17. Monsarrat B, Chatelut E, Royer I, Alvinerie P, Dubois J, Dezeuse A, et al. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 1998; 26:229-233.
18. Formica JV, Regelson W. Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol 1995; 33:1061-1080.
19. Lopez-Lazaro M. Flavonoids as anticancer agents: structure-activity relationship study. Curr Med Chem Anticancer Ag 2002; 2:691-714.
20. Choi JS, Choi HK, Shin SC. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int J Pharm 2004; 275:165-170.
21. Choi JS, Jo BW, Kim YC. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm 2004; 57:313-318.
22. Ong CE, Coulter S, Birkett DJ, Bhasker CR, Miners JO. The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol 2000; 50:573-580.
23. Park JY, Kim KA, Shin JG, Lee KY. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. Br J Clin Pharmacol 2004; 58:397-402.
24. Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 2002; 30:631-635.
25. Niemi M, Kajosaari LI, Neuvonen M, Backman JT, Neuvonen PJ. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol 2004; 57:441-447.
26. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waetcher F, Fabre JM, et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 2001; 29:242-251.